Skip to main content
SpringerLink
Log in

Pancreatic Cancer: Nanoparticle Targeted Therapy Via Epidermal Growth Factor Receptor

  • Chapter
  • First Online:
Hormone Related Cancer Mechanistic and Nanomedicines

Abstract

Pancreatic cancer is the malignant neoplasm of pancreas and has the worst mortality rate with a 5-year survival rate of only 7%. Pancreatic cancer is tough to detect, hard to diagnose, and early to metastasize. Hence, by the time symptoms are diagnosed it may be at higher phases and could have been spread to other organs. Pancreatic cancer is a malignant neoplasm that arises from the cells of pancreas, a glandular organ made of both endocrine and exocrine cells behind the stomach. The role and significance of EGFR in the development and progression of human malignancies highlight the fact that EGFR blockade offers to be a promising therapeutic intervention strategy for cancer. The ligand or the targeting moiety which could be exploited for the development of an efficient targeted nanotherapeutics has to be chosen only after clear understanding about the various strategies which specifically target and block EGFR signaling cascade representing various strategies which have been exploited for targeting EGFR overexpressed on cancer cells as a therapeutic intervention approach for cancer treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Amrutkar M, Gladhaug IP (2017) Pancreatic cancer Chemoresistance to gemcitabine. Cancers (Basel) 9

    Google Scholar 

  • Baines AT, Martin PM, Rorie CJ (2016) Current and emerging targeting strategies for treatment of pancreatic cancer. Prog Mol Biol Transl Sci 144:277–320

    Article  CAS  Google Scholar 

  • Barenholz Y (2012) Doxil®--the first FDA-approved Nano-drug: lessons learned. J Control Release 160:117–134

    Article  CAS  Google Scholar 

  • Bodmer M, Becker C, Meier C, Jick SS, Meier CR (2011) Use of metformin and the risk of ovarian cancer: a case-control analysis. Gynecol Oncol 123:200–204

    Article  CAS  Google Scholar 

  • Bonifazi M, Gallus S, Bosetti C, Polesel J, Serraino D, Talamini R, Negri E, La Vecchia C (2010) Aspirin use and pancreatic cancer risk. Eur J Cancer Prev 19:352–354

    Article  CAS  Google Scholar 

  • Braghiroli MI, de Celis Ferrari ACR, Pfiffer TE, Alex AK, Nebuloni D, Carneiro AS, Caparelli F, Senna L, Lobo J, Hoff PM et al (2015) Phase II trial of metformin and paclitaxel for patients with gemcitabine–refractory advanced adenocarcinoma of the pancreas. Ecancermedicalscience 9:563

    Article  Google Scholar 

  • Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403–2413

    Article  CAS  Google Scholar 

  • Cabasag CJ, Ferlay J, Laversanne M, Vignat J, Weber A, Soerjomataram I, Bray F (2022) Pancreatic cancer: an increasing global public health concern. Gut 71(8):1686–1687

    Google Scholar 

  • Cavalla D (2015) Do no harm. In: Off-label prescribing–justifying unapproved medicine. John Wiley & Sons, Ltd, pp 71–103

    Chapter  Google Scholar 

  • Cerullo M, Gani F, Chen SY, Canner J, Pawlik TM (2016) Metformin use is associated with improved survival in patients undergoing resection for pancreatic cancer. J Gastrointest Surg 20:1572–1580

    Article  Google Scholar 

  • Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul J-L, Gourgou-Bourgade S, de la Fouchardière C et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817–1825

    Article  CAS  Google Scholar 

  • Currie CJ, Poole CD, Gale EAM (2009) The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52:1766–1777

    Article  CAS  Google Scholar 

  • de la Pinta C (2022) Radiomics in pancreatic cancer for oncologist: present and future. Hepatobiliary Pancreat Dis Int 21(4):356–361

    Article  Google Scholar 

  • Donadon V, Balbi M, Ghersetti M, Grazioli S, Perciaccante A, Della Valentina G, Gardenal R, Dal Mas M, Casarin P, Zanette G et al (2009) Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease. World J Gastroenterol 15:2506–2511

    Article  CAS  Google Scholar 

  • Donadon V, Balbi M, Mas MD, Casarin P, Zanette G (2010) Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver Int 30:750–758

    Article  CAS  Google Scholar 

  • Goldberg R (2022) Toward precision pancreatic cancer care. J Natl Compr Cancer Netw 20(5):547–548

    Article  Google Scholar 

  • Goldstein D, El-Maraghi RH, Hammel P, Heinemann V, Kunzmann V, Sastre J, Scheithauer W, Siena S, Tabernero J, Teixeira L et al (2015) Nab–paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. J Natl Cancer Inst 107

    Google Scholar 

  • Gopinath KS (2015) Indian J Surg Oncol 6:1–2

    Article  CAS  Google Scholar 

  • Gou S, Cui P, Li X, Shi P, Liu T, Wang C (2013) Low concentrations of metformin selectively inhibit CD133+ cell proliferation in pancreatic cancer and have anticancer action. PLoS One 8:e63969

    Article  CAS  Google Scholar 

  • Gugenheim J, Crovetto A, Petrucciani N (2022) Neoadjuvant therapy for pancreatic cancer. Updat Surg 74(1):35–42

    Article  Google Scholar 

  • Hamidi-Sofiani V, Rakhshi R, Moradi N, Zeynali P, Nakhaie M, Behboudi E (2022) Oncolytic viruses and pancreatic cancer. Cancer Treat Res Commun 31:100563

    Article  Google Scholar 

  • Hare JI, Lammers T, Ashford MB, Puri S, Storm G, Barry ST (2017) Challenges and strategies in anti-cancer Nanomedicine development: an industry perspective. Adv Drug Deliv Rev 108:25–38

    Article  CAS  Google Scholar 

  • Heinemann V, Boeck S, Westphalen CB (2022) Treatment of metastatic pancreatic cancer. Inn Med (Heidelb) 63(8):851–862

    CAS  Google Scholar 

  • Hosein PJ, de Lima Lopes G, Pastorini VH, Gomez C, Macintyre J, Zayas G, Reis I, Montero AJ, Merchan JR, Rocha Lima CM (2013) A phase II trial of nab-paclitaxel as second-line therapy in patients with advanced pancreatic cancer. Am J Clin Oncol 36:151–156

    Article  CAS  Google Scholar 

  • Huang X, Zhang G, Liang T (2022) Subtyping for pancreatic cancer precision therapy. Trends Pharmacol Sci 43(6):482–494

    Article  CAS  Google Scholar 

  • Immunotherapy for Pancreatic Cancer (n.d.). https://www.cancerresearch.org/we-are-cri/home/cancer-types/pancreatic-cancer. Accessed Feb 5, 2018

  • Kalthoff H (2022) How open is the therapeutic horizon for pancreatic cancer patients? Hepatobiliary Pancreat Dis Int. 21(1):1–3

    Article  Google Scholar 

  • Karnevi E, Said K, Andersson R, Rosendahl AH (2013) Metformin-mediated growth inhibition involves suppression of the IGF-I receptor Signalling pathway in human pancreatic cancer cells. BMC Cancer 13:235

    Article  CAS  Google Scholar 

  • Kartal K, Guan Z, Tang R, Griffin M, Wang Y, Braun D, Klein AP, Hughes KS (2022) Familial pancreatic cancer: who should be considered for genetic testing? Ir J Med Sci 191(2):641–650

    Article  CAS  Google Scholar 

  • Klatte DCF, Wallace MB, Löhr M, Bruno MJ, van Leerdam ME (2022) Hereditary pancreatic cancer. Best Pract Res Clin Gastroenterol 58–59:101783

    Article  Google Scholar 

  • Kordes S, Pollak MN, Zwinderman AH, Mathôt RA, Weterman MJ, Beeker A, Punt CJ, Richel DJ, Wilmink JW (2015) Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo–controlled phase 2 trial. Lancet Oncol 16:839–847

    Article  CAS  Google Scholar 

  • Kristin A (n.d.) Esposito. medications used for the treatment of pancreatic cancer associated with ICD-10 codes. http://oncpracticemanagement.com/issue-archive/2016/january-2016-volume-6-number-1/medications-used-treatment-pancreatic-cancer-associated-icd-10-codes/. Accessed Feb 5, 2018

  • Lee JH, Kim TI, Jeon SM, Hong SP, Cheon JH, Kim WH (2012) The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus. Int J Cancer 131:752–759

    Article  CAS  Google Scholar 

  • Levêque D (2008) Off-label use of anticancer drugs. Lancet Oncol 9:1102–1107

    Article  Google Scholar 

  • Levêque D (2016) Off-label use of targeted therapies in oncology. World J Clin Oncol 7:253–257

    Article  Google Scholar 

  • Li D, Yeung S-CJ, Hassan MM, Konopleva M, Abbruzzese JL (2009) Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 137:482–488

    Article  Google Scholar 

  • Lonardo E, Cioffi M, Sancho P, Sanchez-Ripoll Y, Trabulo SM, Dorado J, Balic A, Hidalgo M, Heeschen C (2013) Metformin targets the metabolic Achilles heel of human pancreatic cancer stem cells. PLoS One 8:e76518

    Article  CAS  Google Scholar 

  • Ma WW, Hidalgo M (2013) The winning formulation: the development of paclitaxel in pancreatic cancer. Clin Cancer Res 19:5572–5579

    Article  CAS  Google Scholar 

  • McDonald OG (2022) The biology of pancreatic cancer morphology. Pathology 54(2):236–247

    Article  CAS  Google Scholar 

  • Mohammed A, Janakiram NB, Brewer M, Ritchie RL, Marya A, Lightfoot S, Steele VE, Rao CV (2013) Antidiabetic drug metformin prevents progression of pancreatic cancer by targeting in part cancer stem cells and mTOR signaling. Transl Oncol 6:649–659

    Article  Google Scholar 

  • Moysan E, Bastiat G, Benoit J-P (2013) Gemcitabine versus modified gemcitabine: a review of several promising chemical modifications. Mol Pharm 10:430–444

    Article  CAS  Google Scholar 

  • Nair V, Pathi S, Jutooru I, Sreevalsan S, Basha R, Abdelrahim M, Samudio I, Safe S (2013) Metformin inhibits pancreatic cancer cell and tumor growth and downregulates Sp transcription factors. Carcinogenesis 34:2870–2879

    Article  CAS  Google Scholar 

  • Onivyde (Irinotecan Liposome Injection) (n.d.) A new treatment option for patients with metastatic pancreatic cancer. http://jhoponline.com/top-issues/2016-issues/august-2016-vol-9-no-3/16849. Accessed Feb 5, 2018

  • Pannala R, Leirness JB, Bamlet WR, Basu A, Petersen GM, Chari ST (2008) Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology 134:981–987

    Article  CAS  Google Scholar 

  • Passero FC, Grapsa D, Syrigos KN, Saif MW (2016) The safety and efficacy of Onivyde (irinotecan liposome injection) for the treatment of metastatic pancreatic cancer following gemcitabine-based therapy. Expert Rev Anticancer Ther 16:697–703

    Article  CAS  Google Scholar 

  • Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R (2007) Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2:751–760

    Article  CAS  Google Scholar 

  • Permert J, Ihse I, Jorfeldt L, von Schenck H, Arnqvist HJ, Larsson J (1993) Pancreatic cancer is associated with impaired glucose metabolism. Eur J Surg 159:101–107

    CAS  Google Scholar 

  • Reni M, Orsi G (2022) Pancreatic cancer: still a cold case? Lancet Oncol 23(8):964–965

    Article  Google Scholar 

  • Reni M, Dugnani E, Cereda S, Belli C, Balzano G, Nicoletti R, Liberati D, Pasquale V, Scavini M, Maggiora P et al (2016) (Ir)relevance of metformin treatment in patients with metastatic pancreatic cancer: an open-label, randomized phase II trial. Clin Cancer Res 22:1076–1085

    Article  CAS  Google Scholar 

  • RIOMET® (metformin hydrochloride oral solution) (n.d.). https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021591s003lbl.pdf. Accessed Feb 5, 2018

  • Rozengurt E, Sinnett-Smith J, Kisfalvi K (2010) Crosstalk between insulin/insulin-like growth Factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer. Clin Cancer Res 16:2505–2511

    Article  CAS  Google Scholar 

  • Sadeghi N, Abbruzzese JL, Yeung S-CJ, Hassan M, Li D (2012) Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clin Cancer Res 18:2905–2912

    Article  CAS  Google Scholar 

  • Schmidt T, Belyaev O, Uhl W, Bruns CJ (2022) Surgical treatment of pancreatic cancer-What is new? Chirurg 93(5):446–452

    Article  Google Scholar 

  • Sebastian R (2017) Nanomedicine–the future of cancer treatment: a review. J Cancer Prev Curr Res 8

    Google Scholar 

  • Sexton RE, Uddin MH, Bannoura S, Khan HY, Mzannar Y, Li Y, Aboukameel A, Al-Hallak MN, Al-Share B, Mohamed A, Nagasaka M, El-Rayes B (2022) Azmi AS connecting the human microbiome and pancreatic cancer. Cancer Metastasis Rev 41(2):317–331

    Article  CAS  Google Scholar 

  • Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65:5–29

    Article  Google Scholar 

  • Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67:7–30

    Article  Google Scholar 

  • Tan X-L, Reid Lombardo KM, Bamlet WR, Oberg AL, Robinson DP, Anderson KE, Petersen GM (2011) Aspirin, nonsteroidal anti-inflammatory drugs, acetaminophen, and pancreatic cancer risk: a clinic-based case-control study. Cancer Prev Res 4:1835–1841

    Article  CAS  Google Scholar 

  • The Cost of Cancer Treatment with Chemothreapy is Going Up (n.d.). http://cancercelltreatment.com/2015/05/13/the-cost-of-cancer-treatment-with-chemothreapy-is-going-up/. Accessed Feb 5, 2018

  • Thomasset SC, Lobo DN (2010) Pancreatic Cancer Surg 28:198–204

    Google Scholar 

  • Tingstedt B, Weitkämper C, Andersson R (2011) Early onset pancreatic cancer: a controlled trial. Ann Gastroenterol 24:206–212

    Google Scholar 

  • Uddin R (n.d.) The disadvantages of chemotherapy. https://www.livestrong.com/article/71774-disadvantages-chemotherapy/. Accessed Feb 5, 2018

  • Vieira DB, Gamarra LF (2016) Advances in the use of Nanocarriers for cancer diagnosis and treatment. Einstein (Sao Paulo) 14:99–103

    Article  Google Scholar 

  • Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN et al (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369:1691–1703

    Article  Google Scholar 

  • Von Hoff DD, Ramanathan RK, Borad MJ, Laheru DA, Smith LS, Wood TE, Korn RL, Desai N, Trieu V, Iglesias JL et al (2011) Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol 29:4548–4554

    Article  Google Scholar 

  • Wakasugi H, Funakoshi A, Iguchi H (2001) Clinical observations of pancreatic diabetes caused by pancreatic carcinoma, and survival period. Int J Clin Oncol 6:50–54

    Article  CAS  Google Scholar 

  • Wang F, Herrington M, Larsson J, Permert J (2003) The relationship between diabetes and pancreatic cancer. Mol Cancer 2:4

    Article  Google Scholar 

  • Wang Z, Lai S-T, Xie L, Zhao J-D, Ma N-Y, Zhu J, Ren Z-G, Jiang G-L (2014) Metformin is associated with reduced risk of pancreatic cancer in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Res Clin Pract 106:19–26

    Article  CAS  Google Scholar 

  • Wang-Gillam A, Li C-P, Bodoky G, Dean A, Shan Y-S, Jameson G, Macarulla T, Lee K-H, Cunningham D, Blanc JF et al (2016a) Nanoliposomal Irinotecan with fluorouracil and Folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet 387:545–557

    Article  CAS  Google Scholar 

  • Wang-Gillam A, Li C-P, Bodoky G, Dean A, Shan Y-S, Jameson GS, Macarulla T, Lee K-H, Cunningham D, Blanc J-F et al (2016b) Updated overall survival analysis of NAPOLI-1: phase III study of Nanoliposomal Irinotecan (nal-IRI, MM-398), with or without 5-fluorouracil and Leucovorin (5-FU/LV), versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with Gemcitabin. J Clin Oncol 34:417

    Article  Google Scholar 

  • What Is Combination Chemotherapy? (n.d.). https://www.verywell.com/what-is-combination-chemotherapy-2248995. Accessed Feb 5, 2018

  • Wilkowski R, Wolf M, Heinemann V (2008) Primary advanced Unresectable pancreatic cancer. Recent Results Cancer Res 177:79–93

    Article  CAS  Google Scholar 

  • Wood LD, Canto MI, Jaffee EM, Simeone DM (2022) Pancreatic cancer: pathogenesis, screening, diagnosis, and treatment. Gastroenterology 163(2):386–402

    Article  Google Scholar 

  • Wright JL, Stanford JL (2009) Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. Cancer Causes Control 20:1617–1622

    Article  Google Scholar 

  • Yu X, Zhang Y, Chen C, Yao Q, Li M (2010) Targeted drug delivery in pancreatic cancer. Biochim Biophys Acta 1805:97–104

    CAS  Google Scholar 

  • Zhang H (2016) Onivyde for the therapy of multiple solid tumors. Onco Targets Ther 9:3001–3007

    Article  CAS  Google Scholar 

  • Zhang Z-J, Zheng Z-J, Kan H, Song Y, Cui W, Zhao G, Kip KE (2011) Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis. Diabetes Care 34:2323–2328

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Bioorganic and Medicinal Chemistry Research Laboratory, Department of Pharmaceutical Sciences, Sam Higginbottom University of Agriculture, Technology and Sciences, Prayagraj, India

    Vivek Dwivedi, Shahnawaz Sameem & Amita Verma

  2. Department of Pharmaceutical Sciences, Faculty of Health Sciences, SHUATS, Allahabad, Uttar Pradesh, India

    Mahfoozur Rahman

  3. Laboratory of Computational Modeling of Drugs, Higher Medical and Biological School, South Ural State University, Chelyabinsk, Russia

    Prateek Pathak

Authors
  1. Vivek Dwivedi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shahnawaz Sameem
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mahfoozur Rahman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Prateek Pathak
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Amita Verma
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Amita Verma .

Editor information

Editors and Affiliations

  1. Department of Pharmaceutical Sciences, Faculty of Health Sciences, SHUATS, Allahabad, Uttar Pradesh, India

    Mahfoozur Rahman

  2. Department of Pharmacology and Toxicology, College of Pharmacy, Umm al-Qura University, Mecca, Saudi Arabia

    Waleed H Almalki

  3. Department of Pharmaceutics & and Pharmaceutical Technology, College of Pharmacy, Taif University, Taif, Saudi Arabia

    Majed Alrobaian

  4. Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India

    Sarwar Beg

  5. Department of Pharmacology, College of Pharmacy, Jouf University, Sakakah, Saudi Arabia

    Khalid S Alharbi

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Dwivedi, V., Sameem, S., Rahman, M., Pathak, P., Verma, A. (2022). Pancreatic Cancer: Nanoparticle Targeted Therapy Via Epidermal Growth Factor Receptor. In: Rahman, M., H Almalki, W., Alrobaian, M., Beg, S., Alharbi, K.S. (eds) Hormone Related Cancer Mechanistic and Nanomedicines. Springer, Singapore. https://doi.org/10.1007/978-981-19-5558-7_6

Download citation

  • DOI: https://doi.org/10.1007/978-981-19-5558-7_6

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-19-5557-0

  • Online ISBN: 978-981-19-5558-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation